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A B S T R AC T
Background: Percutaneous renal denervation (RDN) has 
recently been introduced as a treatment for therapy-
resistant hypertension. Also, it has been suggested that 
RDN may be beneficial for other conditions characterised 
by increased sympathetic nerve activity. There are 
still many uncertainties with regard to efficacy, safety, 
predictors for success and long-term effects. To answer 
these important questions, we initiated a Dutch RDN 
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registry aiming to collect data from all RDN procedures 
performed in the Netherlands. 
Methods: The Dutch RDN registry is an ongoing 
investigator-initiated, prospective, multicentre cohort study. 
Twenty-six Dutch hospitals agreed to participate in this 
registry. All patients who undergo RDN, regardless of the 
clinical indication or device that is used, will be included. 
Data are currently being collected on eligibility and 
screening, treatment and follow-up.
Results: Procedures have been performed since August 2010. 
At present, data from 306 patients have been entered into the 
database. The main indication for RDN was hypertension 
(n = 302, 99%). Patients had a mean office blood pressure of 
177/100 (±29/16) mmHg with a median use of three (range 
0-8) blood pressure lowering drugs. Mean 24-hour blood 
pressure before RDN was 157/93 (±18/13) mmHg. RDN was 
performed with different devices, with the Simplicity™ 
catheter currently used most frequently. 
Conclusion: Here we report on the rationale and 
design of the Dutch RDN registry. Enrolment in this 
investigator-initiated study is ongoing. We present baseline 
characteristics of the first 306 participants. 
K E Y WOR DS
Blood pressure, cardiovascular disease, hypertension, 
kidney function, renal denervation
I N T RODUC T I ON 
Renal denervation
Percutaneous renal sympathetic denervation (RDN) is 
currently being used as a potential treatment for therapy-
resistant hypertension and other conditions associated 
with increased sympathetic activity. The treatment aims 
to disrupt afferent and efferent nerves travelling around 
the renal artery with the intention to lower systemic 
sympathetic activity. 
At the beginning of the initiative for the current registry 
in 2010, RDN was an upcoming therapy for resistant 
hypertension. The initial report in The Lancet showing 
the results from the first 50 patients, was followed by great 
enthusiasm for RDN.1 Because of many uncertainties at 
that time and still, we initiated a national registry.
Since 2009, a range of studies has been conducted 
including many cohort studies (uncontrolled) and some 
randomised controlled trials. Almost all studies reported a 
significant decrease in blood pressure, six to twelve months 
after the procedure.1-5 However, not all trials showed 
superiority of RDN when compared with a control group.6,7 
The largest, the Simplicity HTN-3 trial, a randomised, 
blinded trial, showed no statistically significant effect 
of RDN compared with a sham procedure and so the 
RDN landscape changed in 2014.7 A recently published 
meta-analysis acknowledged the safety of the procedure 
and argued for the identification of responders in future 
trials.8 
Effects
Not only blood pressure effects have been studied; various 
cohort studies showed positive results on other aspects, 
such as an improvement in glucose metabolism and 
cardiac function.9,10 Although these studies were not 
properly controlled, the findings are in line with the 
pathophysiology.11,12 Since nerve ablation is non-selective, 
one can imagine that sensory nerves will also be affected. 
Case reports have been published in which patients with 
kidney-related pain syndromes were successfully treated 
by RDN.13,14 
Predictors
Effort has been made to identify characteristics, both 
patient and procedure related, that seem to predict 
a better outcome after RDN. For example, the use of 
aldosterone antagonists, the number and location of 
ablations, office systolic blood pressure at baseline, the 
estimated glomerular filtration rate (eGFR) and the 
presence of diabetes mellitus have been mentioned as 
predictors for efficacy of RDN.15-19 Most of these possible 
predictors could not be confirmed in other studies or 
even contradicting relations were suggested.15,17,18,20 These 
conflicting data underscore the need for more extended 
research.
Safety
Overall, the intervention appeared to be safe. Some cases of 
renal artery stenosis during follow-up were reported. The 
reported rates of vascular complications range from 0.3% 
to 4.3%.4,7,20-23 Time between procedure and renal artery 
imaging varied from six months to three years. Three years 
is the longest follow-up after RDN that has been described 
in literature, for both efficacy and complication rate.21,24 
To date, there are no reports on the effects of RDN on the 
cardiovascular event rate or mortality.
Registration
It is clear that there are still many uncertainties with 
regard to patient selection, effectiveness and complications, 
especially long-term outcomes. Available information is 
predominantly based on small and strictly selected patient 
groups. Follow-up details are scarce and reports on the 
comparison of different devices, or on consistently shown 
predictors for success, are lacking. The Dutch RDN registry 
initiative is designed to combine all Dutch data on RDN 
from routine clinical practice in order to contribute to 
clarifying the effects of this treatment. 
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OB J E C T I V E S 
The main goal is to collect data concerning three important 
issues: safety, predictors for success and the long-term 
effects of RDN. 
Safety 
1. What are the short- and long-term procedural-related 
complications? 
Predictors 
2. What are the predictors for a beneficial effect on 
blood pressure, in particular patient-related factors and 
procedural-related factors? 
3. Is the effectiveness of the currently available RDN 
devices comparable? 
Long-term effects 
4. What is the effect on blood pressure at various time 
points, up to at least five years after RDN? 
5. What is the effect on kidney function at various time 
points, up to at least five years after RDN?
6. What are the cardiovascular event rates, in strata of 
achieved blood pressure level?
MAT E R I A L S  A N D  M E T HODS 
Design and population
The Dutch RDN registry is an ongoing investigator-
initiated, prospective, multicentre cohort study. Twenty-six 
Dutch hospitals agreed to participate in this registry 
(Appendix A). This is approximately 28% of all hospitals 
in the Netherlands and includes, to our knowledge, all 
hospitals in which RDN is being performed. Despite 
willingness to share data on RDN, not all participating 
centres have entered data at the time of writing. All 
patients who underwent RDN, regardless of indication for 
RDN or the device that was used, are to be included in the 
registry. Patients must be at least 18 years of age, but there 
are no other specific inclusion or exclusion criteria. The 
indication for RDN is left to the discretion of the treating 
physician. Endpoint analyses will be stratified according 
to indication for treatment, and analyses on safety and 
long-term effects will be performed based on the total 
cohort. The registry was originally initiated to include 
1000 patients within 36 months, with a minimal duration 
of five years. Given the current enrolment rate, this period 
is being extended. 
Sample size considerations
At the start of the registry, several sample size 
considerations were discussed, based on addressing the 
research questions. With 1000 participants we estimated 
to detect a procedural complication rate of at least 1% with 
sufficient precision (between 0.38% and 1.6%). Based 
on the reports by Esler et al., 8% of the participants who 
underwent RDN actually increased usage of blood pressure 
lowering drugs.2 In the same study, 10% of the patients 
who underwent RDN had a systolic arterial pressure drop 
< 10 mmHg. If these findings are consistent, we expect 
that 80-100 patients in our cohort of 1000 patients can be 
considered to be ‘failures’ or ‘non-responders’. This would 
allow for the evaluation of 8-12 factors for the development 
of a prediction rule to estimate the risk of failure based 
on baseline characteristics.25-28 Importantly, to be able to 
identify responders, we believe that blood pressure change 
after RDN should be adjusted for the change in blood 
pressure lowering medication. 
With regard to the long-term effects, we assume to 
have sufficient precision to estimate treatment effects 
on blood pressure and renal function overall and for 
various subgroups (age, sex, baseline blood pressure, 
renal function). Furthermore, event rates observed in the 
registry will be compared with unpublished estimates 
of cardiovascular event risks in patients with therapy-
resistant hypertension, obtained from existing Dutch 
cohorts (approximately 8% (95% CI 6.3, 9.6)) within three 
years.29,30 Potential confounding factors will be taken into 
account. We will be able to detect an event rate of 5% (95% 
CI 3.6, 6.4) or lower in the RDN cohort, which means a 
statistically significant reduction in cardiovascular risk.
Baseline, procedure and follow-up
Information from the first visit to the outpatient clinic and 
subsequently the investigations to determine eligibility will 
be collected (table 1). 
Recommended follow-up visits are at 3, 6, 9, 12, 18, 24, 
30, 36, 48 and 60 months after RDN. We aim to continue 
annual follow-up of the patients after these 60 months 
as well. Table 1 shows a list of proposed pre-procedural, 
procedural and follow-up variables that are recommended 
to be registered. All participating centres received the list 
of variables at the start of the study. This can be used as a 
guideline and is not mandatory. Nevertheless, some data 
are specifically recommended and part of the standard care 
in most hospitals following the Dutch guideline on RDN:31 
office blood pressure and heart rate (both as a mean of 
three measurements), serum creatinine, weight and data 
on medication use, events and complications. Moreover, 
24-hour ambulatory blood pressure measurement data are 
collected, as is annual measurement of urine creatinine 
and protein levels and imaging of the kidneys (and renal 
arteries) at 12 and 36 months. For follow-up imaging, 
the same modality as during screening for eligibility is 
preferably used. 
As stated before, most objectives and therefore most 
information will be gathered from patients who suffer 
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from therapy-resistant hypertension and we expect this to 
be the predominant indication for RDN. Event follow-up 
(defined below) is obtained in two ways. Firstly, information 
is collected through the data entry in the database by the 
individual investigator. Secondly, the dataset is linked 
with the Dutch Hospital Discharge Register (HDR) (the 
LMR) and with Statistics Netherlands (the CBS) to obtain 
information on hospital discharge diagnoses and causes of 
death, respectively. 
Outcome parameters, definitions and data analysis
Outcome of the stated objectives will be based on the 
following parameters. 
Short-term procedural complications: haematoma, 
bleeding, false aneurysm, renal artery perforation or 
dissection, renal failure, adverse contrast effects, infection, 
and death. This will be presented as percentages by age and 
sex with corresponding 95% confidence limits. Additional 
analyses will be performed to relate patient characteristics 
to the risk of short-term complications. For these analyses, 
multilevel multivariable (logistic) regression models will 
be used. 
Long-term procedural and effect complications: renal 
artery stenosis or other vascular complications, decline in 
kidney function, (orthostatic) hypotension. Data will be 
presented as incidence rates (per person-years of follow-up) 
by age and sex with 95% confidence limits. Additional 
analyses will be performed to relate patient characteristics 
and procedural aspects to the risk of short- and long-term 
complications using multilevel multivariable regression 
models. Results will be reported as hazard ratios with 
corresponding 95% confidence limits.
Change in blood pressure and kidney function at various 
time points: change over time will be analysed by use of 
linear mixed-effects models. Factors that contribute to the 
initial effects and to the long-term effects will be assessed. 
(‘Responder’ has already been defined). Multilevel 
multivariable regression models will be used to explore 
the relation between responders and non-responders and 
baseline characteristics /procedural characteristics. Results 
will be presented as hazard ratios with corresponding 95% 
confidence limits. Stratified analyses will be performed in 
strata of ‘blood pressure measurement with and without 
being on medication’. The results from the regression 
model will be used to make a prediction rule with which 
the absolute probability of success or failure will be 
estimated from baseline characteristics.
Safety analyses and effectiveness endpoints stratified 
per device: the different devices will be related to the 
magnitude of the blood pressure change using univariable 
Table 1. Measurements, laboratory testing and imaging variables, largely as part of routine clinical care in the 
Netherlands31 
Parameters Time points
Patient characteristics and 
history
-  Age, sex, medical history, height 
- Medication review, weight, complaints, renal or 
cardiovascular events requiring admission
First visit
Every visit
Blood pressure and heart rate -  Office BP and heart rate (average of 3 readings)
-  Orthostatic hypotension test








Pre-procedural, 12 and 36 months
Laboratory testing: blood -  Sodium, potassium, creatinine, haemoglobin, 
CRP, insulin, C-peptide, glucose, cholesterol, 





Laboratory testing: urine -  Sample: Creatinine, albumin, C/A ratio
-  24-hour collection: Sodium, potassium, creatinine, 
protein, albumin, catecholamines, cortisol 
Annually
Pre-procedural
Renal denervation Treated arteries, successful ablations, ablation time, 
mean temperature, mean impedance drop, mean 
power, periprocedural complications, device used, 
amount of contrast and radiation used
Procedural
BP = blood pressure; ABPM = ambulatory blood pressure measurement; MR = magnetic resonance; CT = computed tomography; CRP = C-reactive protein; 
HDL = high-density lipoprotein; LDL = low-density lipoprotein; ACE = angiotensin converting enzyme; C/A = creatinine/albumin.
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and multivariable regression models. Multilevel 
multivariable regression models will be used to adjust for 
potential confounding (by indication) variables. 
Rate of events requiring admission: acute coronary 
syndrome, transient ischaemic attack, ischaemic or 
haemorrhagic cerebrovascular accident, peripheral arterial 
ischaemia, congestive heart failure, renal failure and 
mortality. Analyses with regard to risk of events, in 
strata of baseline and/or follow-up characteristics, will 
be performed using multilevel multivariable regression 
models.
Furthermore, as a general approach, in all analyses 
differences across centres will be explored.
Ethical considerations
The registry is being conducted according to the principles 
of the Declaration of Helsinki and in accordance with the 
Medical Research Involving Human Subjects Act (the 
WMO). Patients are informed about the procedure by 
their treating physician. This registry is approved by the 
Medical Research Ethics Committee of the University 
Medical Centre Utrecht and registered at ClinicalTrials.
gov: NCT02482103.
Data management
All data are entered into a web-based electronic Case 
Report Form. Data management is performed by the 
Julius Center for Health Sciences and Primary Care 
at the University Medical Centre Utrecht, Utrecht, the 
Netherlands.
Sponsoring
This study is initiated and supported by the University 
Medical Center Utrecht in the Netherlands. Funding 
is in part obtained from the Dutch Kidney Foundation 
(Nierstichting), project number CPI12.02.
R E SU LT S 
General description
On 23 March 2015, data of 306 patients had been entered 
into the database (inclusions per centre are shown in 
Appendix B). Procedures have been performed since August 
2010. Table 2 shows the available baseline characteristics of 
these patients, enrolled by 20 hospitals. In 302 patients, the 
indication for RDN was hypertension. Four patients were 
treated because of kidney-related pain syndromes. 
Blood pressure
Blood pressure is shown as office measurements and 
as 24-hour measurements when available (table 3). In 
almost half of the patients, the 24-hour measurement 
was performed during a period of partial or complete 
medication stop, due to centre-specific investigations.32 
The overall mean systolic 24-hour blood pressure was 
157±18 mmHg. Approximately 25% of the patients 
had a mean daytime systolic blood pressure of more 
than 175 mmHg. Mean office blood pressure was 
177±29 mmHg.
Medication
In table 2 the medication details are presented. The 
prescribed medications of the patients who temporarily 
stopped their treatment are taken into account in this 
table. Therefore, medication use corresponds with office 
blood pressure values but not with 24-hour values. The 
most commonly used drugs were renin-angiotensin-
aldosterone system (RAAS) inhibitors (79%), diuretics 
(70%), calcium-channel blockers (64%), beta-blockers 
(61%) and alpha-blockers (23%). The use of other blood 
pressure lowering drugs (centrally-acting sympatholytic 
agents, direct-acting vasodilating drugs and nitrates) was 
low (11%). Aldosterone antagonists (mainly spironolactone) 
were used by 25% of the individuals. The median 
number of prescribed antihypertensive drugs was three, 
ranging from 0-8, with a mean daily use of 5.4±3.7 units. 
Interestingly, 14 patients did not use any blood pressure 
lowering drugs at all. Five of these patients were intolerant 
to many different drugs. Another five of these patients have 
never used any antihypertensive drugs, due to borderline 
hypertension. Of the remaining four patients, it was 
unknown why no antihypertensive drugs were prescribed. 
Device
The most frequently used device for RDN was the 
Symplicity™ catheter (Medtronic, Santa Rosa, CA, USA) 
(88%). Apart from the Simplicity™ catheter, four other 
devices were used in more than 10% of the cases. 
Comorbidities
The presented comorbidities in table 2 are based on the 
medical history (not on medication use). Dyslipidaemia 
was present in 42% of the cases and approximately 21% of 
the patients were diagnosed with diabetes mellitus. 
D I S CUS S I ON
We report the first baseline characteristics from an 
investigator-initiated national registry for RDN. The Dutch 
RDN registry strives for complete coverage, which means 
that all patients who underwent an RDN procedure in the 
Netherlands are to be included. Inclusion is not restricted 
by specific criteria. Therefore, these data represent 
real-world clinical practice of RDN in the Netherlands. 
The main underlying reason for this initiative is that 
including the data from all centres and all patients in 
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one study provides faster and more valuable insight into 
complications and effectiveness when compared with 
single-centre reports with relatively small numbers of 
patients. This is especially important for RDN since this 
new procedure is at the beginning of evaluation in routine 
clinical practice. Furthermore, a registry may lead to 
uniformity in data collection, which allows for pooling 
of the data. Finally, for identification of predictors of 
response, a large number of patients is needed.
Globally, RDN has been performed on a large scale. 
Unfortunately, only a fraction of the treated patients 
has been adequately registered. We estimate, based on 
correspondence with manufacturers and hospitals, that 
approximately 70% of the performed procedures in 
the Netherlands are currently included in this registry. 
Several registries exist world-wide, of which the Global 
SYMPLICITY registry, initiated by Medtronic, contains 
the largest number of patients. Its baseline data were 
published in 2013 and the first results in 2015.33,34 An 
important aspect is that the Symplicity™ catheter was 
exclusively used in the Global SYMPLICITY registry. 
Due to former reimbursement policies, this device was 
also most frequently used in the Netherlands up to 2014. 
Since late 2014, the multi-electrode EnligHTN™ catheter 
Table 2. Selection of baseline characteristics from 
participants in the Dutch RDN registry
All patients 
(n=306)





eGFR (ml/min/1.73 m2) 82 (±20)
eGFR<60 12%
Body mass index (kg/m2) 29.4 (±5.0)
Comorbidity
Dyslipidaemia 42%






OneShot™ Renal Denervation Systema 1%
Vessix™ Renal Denervation Systemb 1%
Other 0.5%
No. of antihypertensive drugs 3 (0-8)





Double RAAS inhibition 8%





Other blood pressure lowering drugs 11%
Continuous variables are presented as a mean (±SD) or as median (range). 
Categorical variables are presented as absolute number and/or percentage. 
eGFR = estimated glomerular filtration rate; RAAS = renin-angiotensin-
aldosterone system; ACEi = angiotensin-converting enzyme inhibitor; ARB 
= angiotensin receptor blocker. aCovidien, Mansfield, MA, USA. bBoston 
Scientific, Marlborough, MA, USA. ccalculated by use of conversion factors 
as provided by the World Health Organization (http://www.whocc.no/
atcddd/).




Systolic (mmHg) 177 (±29)
Diastolic (mmHg) 100 (±16)
Ambulatory blood pressure
24-hour systolic (mmHg) 157 (±18)
24-hour diastolic (mmHg) 93 (±13)
24-hour heart rate (bpm) 74 (±12)
Daytime systolic (mmHg) 162 (±19)
Daytime diastolic (mmHg) 97 (±13)
Nighttime systolic (mmHg) 146 (±20)
Nighttime diastolic (mmHg) 84 (±13)
Mean daytime blood pressure categorised
Systolic <135 (mmHg) 3%
Systolic 135-154 (mmHg) 34%
Systolic 155-174 (mmHg) 38%
Systolic ≥175 (mmHg) 25%
Continuous variables are presented as a mean (±SD). Categorical variables 
are presented as percentage; bpm=beats per minute.
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(St Jude Medical, St Paul, MN, USA) has also been 
approved for conditional reimbursement. 
In the literature, RDN was introduced as treatment for 
therapy-resistant hypertension, defined as a blood pressure 
≥ 140/90 mmHg despite appropriate lifestyle measures 
and the use of a diuretic and two other antihypertensive 
drugs (adequately dosed).35 These data show that in clinical 
practice, this definition was not guiding the selection of 
patients: several patients did not use three or more drugs 
and diuretics were only prescribed in 70% of the cases. 
There are few other RDN registries that we are aware 
of. Table 4 gives an overview of the results of our search 
in PubMed, trial registers and Google on 1 June 2015, 
using the search terms “renal denervation” and “registry”. 
Multicentre investigator-driven registries for RDN 
regardless of device, such as the present registry, seem to 
be scarce. However, we may not have found all registries 
using the above-mentioned sources and search terms. It 
is of importance to note that patients registered in our 
registry can also be registered elsewhere, since it is up to 
the principal investigator of the centre to decide whether or 
not to participate in other registries. This is a relevant issue 
when data from various registries are pooled. The Dutch 
registry and the Global SYMPLICITY registry differ in 
several ways, for example with regard to comorbidities and 
prescribed drugs. In the Global SYMPLICITY registry, the 
prevalence of diabetes mellitus and chronic kidney disease 
is considerably higher (41% vs. 21% and 22% vs. 12% in 
the Dutch RDN registry) and sympathetic blocking agents, 
both beta-blockers and centrally-acting sympatholytic 
drugs, are prescribed far more often (77% vs. 61% and 
40% vs. < 11% in the Dutch RDN registry). 
Although hypertension is the main indication for RDN 
in the majority of patients, the dataset contains a few 
patients who underwent RDN to treat kidney-related pain 
syndromes. So far, percutaneous RDN for this specific 
indication has only been described in case reports.13,14 
Furthermore, the Dutch registration aims to collect 
detailed procedural information that might be related 
to outcome. In the literature, several procedural aspects 
have been related to a better outcome. A previous study 
revealed a positive correlation between the number of 
ablation points and the reduction in office blood pressure 
after RDN.15 Also a positive relation between the ablation 
Table 4. Overview of renal denervation registries from PubMed, Google and trial registers as of 1 June 2015
Registry name Publications Recruiting Single/multi 
centre
Initiator Device used
Global SYMPLICITY Registry (incl. 
GREAT from Germany)
201433 Yes Multi Medtronic Symplicity™
UK Renal Denervation Affiliation (UK) No1 Yes Multi Investigator No restriction
IRRD (Italy) No2 Yes Multi Investigator Unknown
Heidelberg registry (Heidelberg, 
Germany)
201437 Unknown Single Investigator Symplicity™
ALSTER BP registry (Hamburg, 
Germany)
201417 Yes Single Investigator Symplicity™
Symplicity Venezuelan Registry 
(Venezuela)
Poster abstract JACC 
20133
Unknown Multi Investigator Symplicity™
RDN-POL (Poland) Presentation at LINC 
20134
Unknown Multi Investigator Symplicity™
RDN registry (Lisbon, Portugal) 201438 Unknown Single Investigator No restriction
TREND (Austria) Abstract J. für 
Hypertonie 20145
Yes Multi Investigator No restriction
IBERIS – HTN Registry No6 Yes Multi Terumo 
Europe N.V.
Iberis™ system
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points placed close to the kidney and the reduction in 
blood pressure was found.15,16 Follow-up data from the RDN 
registry might contribute to these findings. 
Methodological challenges
The initiation of a national registry using data that 
are routinely collected has a number of methodological 
challenges that may hamper the validity of the findings. 
Without being exhaustive, a few important ones are 
mentioned. Firstly, the issue around ‘confounding by 
indication’, that is the effect of patient selection on the 
outcome of the study, is likely to be of importance, 
especially when investigating predictors for success.36 
Measurement of potential confounders may take away part 
of the problem. 
Secondly, differences across centres in contribution to the 
registry (size) and difference in measurement protocols 
are inevitable, but may prove to be important. Therefore, 
as mentioned in the ‘Materials and Methods’ section, 
differences across centres will be explored in all analyses. 
The third challenge, especially in RDN, is adherence to 
medication. Our registry in its current phase is based on 
routine clinical practice. In that setting, information on 
adherence is not routinely collected. In addition, tools to 
monitor adherence all have their limitations, and drug 
levels in blood are generally not measured in these patients. 
CONC LUS I ON
Renal denervation is a promising treatment for patients 
suffering from therapy-resistant hypertension or other 
diseases related to sympathetic overactivity. The Dutch 
RDN registry is a collaboration of 26 hospitals in the 
Netherlands, initiated with the intention to increase our 
knowledge of this therapy by pooling data of all patients 
treated with RDN in the Netherlands. Combining data 
from all centres in one registry should result in faster and 
more valuable insight into complications and effectiveness, 
when compared with single-centre cohorts. At the time of 
writing, 306 patients have been included. Detailed analyses 
will follow, reporting on safety, effectiveness, predictors 
of response and potential differences between currently 
available devices. 
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Appendix A. Participating centres (alphabetical order)
Academic Medical Center Amsterdam B.J.H. van den Born1, MD, PhD
P.M. van Brussel2, MD
1Department of Internal Medicine
2Department of Cardiology
Albert Schweitzer Hospital Dordrecht P.H.M. van der Valk1, MD
P.J.H. Smak Gregoor2, MD, PhD 
M.R. Korte2, MD, PhD
1Department of Radiology
2Department of Nephrology
Amphia Hospital Breda M. Meuwissen1, MD
1Department of Cardiology
Canisius-Wilhelmina Hospital Nijmegen M.E.R. Gomes1, MD, PhD 
T. Oude Ophuis1, MD, PhD
M. Kruisbergen1
1Department of Cardiology
Catharina Hospital Eindhoven E. Troe2, MANP
W.A.L. Tonino1, MD, PhD
C.J.A.M. Konings2, MD, PhD
P. Douwes-Draaijer2, MD, PhD
M.R.H.M. van Sambeek3, MD, PhD
B.R.G. Brueren1, MD, PhD
H.J.T.M. Hendrix- van Gompel1
1Department of Cardiology
2Department of Internal Medicine 
3Department of Surgery
Erasmus Medical Center Rotterdam J. Daemen1, MD, PhD
A.H. van den Meiracker2, MD, PhD 
1Department of Cardiology
2Department of Vascular Medicine
Haga Hospital The Hague M. Bax1, MD
I.M. van der Meer2, MD, PhD
H. van Overhagen3, MD, PhD
M. van Buren2, MD, PhD
L.C. van Dijk3, MD, PhD
C.E. Schotborgh1, MD
1Department of Cardiology
2Department of Internal Medicine
3Department of Radiology
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Hospital Group Twente Almelo/Hengelo P.A.M. de Vries1, MD
A. van Balen1
1Department of Internal Medicine
Isala Clinics Zwolle J.E. Heeg1, MD, PhD
J.J.J. Smit2, MD, PhD
A. Elvan2, MD, PhD
M.R. de Jong2, MD
B.A.A.M. van Hasselt3, MD
1Department of Internal Medicine
2Department of Cardiology
3Department of Radiology
Leiden University Medical Center Leiden J.I. Rotmans1, MD, PhD
B.L. van der Hoeven2, MD, PhD
A. Hage1
A.J. Rabelink1, MD, PhD




Maastricht University Medical Center Maastricht A.A. Kroon1, MD, PhD
M.W. de Haan2, MD, PhD
M. Das2, MD, PhD
H.A. Jongen-Vancraybex1 
E.G.M. Herben1 
1Department of Internal Medicine
2Department of Radiology
Martini Hospital Groningen R. Steggerda1, MD
S.M.L. Niamut2, MD
1Department of Cardiology
2Department of Internal Medicine
Medical Center Alkmaar Alkmaar J.O.J. Peels1, MD, PhD
J.B.R.M. de Swart1, MD
1Department of Cardiology
Medical Center Haaglanden The Hague A.J. Wardeh1, MD, PhD 
J.H.M. Groeneveld2, MD
E. van der Linden3, MD, PhD
1Department of Cardiology
2Department of Internal Medicine
3Department of Radiology




Medisch Spectrum Twente Enschede M.G. Stoel1, MD, PhD
G.D. Kant2, MD
1Department of Cardiology
2Department of Internal Medicine
Onze Lieve Vrouwen Gasthuis Amsterdam J.P.R. Herrman1, MD, PhD
S. van Wissen2, MD, PhD
M. Khan1, MD
J.G.A.M. Blomjous3, MD 
K. Koers1, MD
J. van Etten1, MD 
1Department of Cardiology
2Department of Internal Medicine
3Department of Radiology
Radboud University Medical Center Nijmegen J. Deinum1, MD, PhD
S.W. Westra2, MD
1Department of Internal Medicine
2Department of Cardiology
Rijnstate Hospital Arnhem W.R.M. Aengevaeren1, MD, PhD
K.J. Parlevliet2, MD, PhD
1Department of Cardiology 
2Department of Nephrology
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Scheper Hospital Emmen A. Schramm1, MD, PhD
G.A.J. Jessurun1, MD, PhD
1Department of Cardiology
St. Antonius Hospital Nieuwegein B.J.W.M. Rensing1, MD, PhD
1Department of Cardiology
TweeSteden Hospital Tilburg M.H.M. Winkens1, MD
T.K.A. Wierema2, MD, PhD
E. Santegoets1
1Department of Cardiology
2Department of Internal Medicine
University Medical Center Groningen Groningen E. Lipsic1, MD, PhD
E. Houwerzijl2, MD, PhD
M. Kater3, MD
1Department of Cardiology
2Department of Internal Medicine
3Department of Radiology
University Medical Center Utrecht Utrecht M.F. Sanders1, MD
P.J. Blankestijn1, MD, PhD
M.L. Bots2, MD, PhD
M. Voskuil3, MD, PhD
W. Spiering4, MD, PhD
E.J. Vonken5, MD, PhD
M.M.A. Beeftink3, MD 
R.L. de Jager1, MD
W.L. Verloop3, MD, PhD 
E.E. Vink1, MD, PhD
P.A. Doevendans3, MD, PhD 
1Department of Nephrology
2Julius Centre for Health Sciences and Primary Care
3Department of Cardiology
4Department of Vascular Medicine
5Department of Radiology
VU Medical Center Amsterdam C.P. Allaart1, MD, PhD 
A. Nap1, MD, PhD
1Department of Cardiology
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